Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Isogenica, Cresset Group and Biolauncher Secure Funding from UK’s Technology Strategy Board

Published: Thursday, June 07, 2012
Last Updated: Wednesday, June 06, 2012
Bookmark and Share
Funding for a £1M project to develop new small molecule drug platform.

Isogenica and Biolauncher, Cambridge UK together with Cresset Group, Welwyn Garden City UK have announced funding from the Technology Strategy Board, the UK’s innovation agency, for a £1M project to develop a highly-scalable approach to small molecule drug discovery.

The funding enables the consortium to develop an integrated platform to identify diverse small molecules active against drug targets using very large peptide libraries to explore chemical space.

The consortia’s objective is to demonstrate that this platform provides a new scalable approach to the early stage drug discovery challenges that is rapid, cost effective and applicable to intracellular, extracellular and membrane bound drug targets.

The process will use Isogenica’s libraries to select a population of diverse binding peptides against a biological target. These peptides will be analyzed using novel structural bioinformatics already developed by Biolauncher to identify their active conformation.

This three-dimensional template will be used to generate a field based pharmacophore that Cresset will use to identify small molecule drug-like medicinal chemistry starting points.

Individually the component technologies have been used in over 170 drug discovery projects to date.

“The diversity of the chemical libraries in corporate collections can be quite limited and so the percentage of chemical space represented is small. Isogenica’s peptide libraries are designed to be structurally very diverse and sample a much greater volume of chemical space. Also, in addition to acting as a structural template, there is a high probability of finding binding peptides which have immediate utility as reagents for probing the target biology and supporting the drug development process” commented Rowan Gardner, who is leading the consortia’s Business Development activity.

“By working with diverse populations of binding peptides it is possible to determine which residues are contributing to the binding and infer their active conformations. Coupling Isogenica’s massive screening libraries with Cresset’s small molecule bioisostere discovery tools offer the possibility to bridge biologics directly into small molecule chemistry” added Kevin Mathews, CEO of Isogenica.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

International Symposium on Compound Design Technologies
The symposium will be held on March 19th at the British Embassy in Tokyo and on March 20th at the British Consulate-General in Osaka.
Thursday, February 06, 2014
Cresset Grows Scientific Team
Company relocates to offices in Cambridge Cluster.
Thursday, August 22, 2013
Cresset Announces Excellent 2012 Sales Figures and Growth
Cresset provides computational chemistry software and consulting services.
Tuesday, January 22, 2013
Cresset Expands Professional Services Division
Cresset now provides more flexible service options including daily pricing, full project support and software-as-a-service.
Wednesday, February 01, 2012
Scientific News
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
Making Genetic Data Easier to Search
Scripps team streamlines biomedical research by making genetic data easier to search.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!